ClinicalTrials.Veeva

Menu

Posterior Reversible Encephalopathy Syndrome in the Critically Ill Patients

I

Ictal Group

Status

Enrolling

Conditions

Posterior Reversible Encephalopathy Syndrome

Treatments

Other: No intervention

Study type

Observational

Funder types

Other

Identifiers

NCT03470467
ICTAL PRES REGISTRY

Details and patient eligibility

About

Posterior Reversible Encephalopathy Syndrome prospective (PRES) registry. Data collection using a standardized form : demographic data and data related to the PRES, including circumstances of onset, dates and times of onset and of symptoms control, on-scene clinical findings, clinical and radiological features of PRES, pre-hospital and hospital care providers, timing of antiepileptic, antihypertensive drugs and supportive treatments, results of etiological investigations, cause of PRES, type and dosage of antiepileptic and antihypertensive drugs. Dates and times of EEG monitoring, EEG results, radiological and biological investigations. Outcomes including vital status and Glasgow Outcome Scale score at ICU and hospital discharge, day-90 and 1-year after SE and determined based on data in the ICU and/or neurologist charts and/or patients phone interview

Enrollment

300 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • age >= 18 years

  • Posterior Reversible Encephalopathy Syndrome defined as:

    • combination of consciousness impairment, seizure activity, headaches, visual abnormalities, nausea/vomiting, and focal neurological signs AND
    • cerebral imaging abnormalities involving the white matter (brain CT scan hypodensities AND/OR Brain MRI hypoT1, hyper T2 FLAIR)
  • intensive care unit admission

Exclusion criteria

  • normal cerebral imaging

Trial contacts and locations

1

Loading...

Central trial contact

Stephane LEGRIEL, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems